An interventional study of nutritional intervention and Exercise in Sarcopenia in Elderly, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Sarcopenia with a site in China — 46 open to participants now, 51 under way, 4 of them phase 3. Sarcopenia · China.
Among the 82 studies in Sarcopenia with a site in China, this one is the 21st largest by planned enrollment of the 51 interventional ones that give a count, is one of 15 that started in 2026, is one of 41 with no phase, reaches primary completion later than 25 of the 50 other live ones, and was the 82nd registered.
1,330 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →46 of the 82 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 60+
GuangZhou Cellgenes Biotechnology Co., Ltd. · Sites in China
Ages 50–85
Peking Union Medical College Hospital · Sites in China
Ages 18+
China Medical University, China · Sites in China
Ages 18+
Zhejiang Hospital · Sites in China
Ages 50–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 245 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 3
First in 2012; this study’s year is marked. 15 started in 2026.
This study's planned enrollment of 120 is above the median of 60 across 855 interventional studies indexed under Sarcopenia.
Median enrollment 113 across the 51 interventional studies, 868 across the 31 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 82 have an industry lead sponsor. The 10 most frequent:
Shanghai Yueyang Integrated Medicine Hospital is the lead sponsor of 39 studies on the registry; 16 are open to participants now.
Shanghai Yueyang Integrated Medicine Hospital has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
13 of the studies in Sarcopenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07049731Weiwei MaImprovement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise | 2026-12 |
| NCT07724587Ningbo Medical Center Lihuili HospitalThe Effectiveness and Safety of Combined Research on Uremic Sarcopenia | 2026-12-01 |
| NCT07059871Zhejiang HospitalA Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. | 2026-12-30 |
| NCT07538674Shanghai Yueyang Integrated Medicine HospitalPeiyuan Guben Tongluo Ointment for Elderly Sarcopenia | 2027-03-31 |
| NCT06643780Prince of Wales Hospital, Shatin, Hong KongRANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 82 studies in Sarcopenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will enroll older adults with sarcopenia (Spleen-Kidney Deficiency Pattern) who will receive exercise and nutritional interventions. By assessing changes from baseline in DXA-measured appendicular muscle mass and other efficacy outcomes, the study aims to characterize the longitudinal changes in sarcopenia over a 24-week period and provide an external control for a future randomized, double-blind clinical trial of Peiyuan Guben Tongluo Ointment in older adults with sarcopenia (Spleen-Kidney Deficiency Pattern).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Provide protein and vitamin D supplementation.
Receive standardized Baduanjin training with unified movements; the training is conducted 3 times weekly, starting 3 hours after meals, with a duration of 30 minutes per session. Intervention
DXA-measured appendicular skeletal muscle mass
Detected by dual-energy X-ray absorptiometry (GE Healthcare, DXA). The skeletal muscle mass index (SMI) is defined as the ratio of DXA-measured skeletal muscle mass to the square of height.
Time frame: Baseline, week 12, week 24
Upper limb handgrip strength
Use a hand dynamometer to record grip strength data for comparison.
Time frame: Up to 24 weeks
Handgrip strength
Use a hand dynamometer to record grip strength data for comparison.
Time frame: Baseline, week 12, week 24
Timed Up and Go test (TUG)
Subjects shall sit on a chair with a seat height of 46 cm, a straight backrest and armrests (armrest height approximately 65 cm). They are required to stand up with minimal assistance from the armrests. The total time is recorded from leaving the backrest to standing upright, walking 3 meters at their usual walking speed, turning around, walking back, and sitting down fully against the chair back. The average value of three trials is calculated. Elderly individuals who routinely use walking aids may use them during the test.
Time frame: Baseline, week 12, week 24
Berg Balance Scale (BBS)
The scale consists of 14 items in total, including sitting to standing, standing to sitting, standing unsupported, standing with eyes closed, reaching forward with outstretched arms, turning 360 degrees, alternating foot placement on a step, single-leg standing, etc. All items take 10-15 minutes to complete. Each item is scored from a minimum of 0 points to a maximum of 4 points, with a total possible score of 56 points. A higher score indicates better balance function; a score below 40 points suggests an increased risk of falls.
Time frame: Baseline, week 12, week 24
TCM Syndrome Score
In accordance with the scoring criteria specified in the 《Guiding Principles for Clinical Research of New Traditional Chinese Medicine Drugs》, the total score for \*\*Spleen-Kidney Deficiency Syndrome\*\* was calculated.
Time frame: Baseline, week 12, week 24
Mini Nutritional Assessment (MNA)
Nutritional status was evaluated using the Mini Nutritional Assessment (MNA). This scale comprehensively evaluates an individual's nutritional status through a series of questions covering body weight, dietary intake, mobility, mental state and other aspects. The full score of the scale is 30 points. Grading criteria: a total score ≥ 24 indicates good nutritional status; a score between 17 and 24 suggests risk of malnutrition; a total score below 17 confirms definite malnutrition.
Time frame: Baseline, week 12, week 24
Activities of Daily Living (ADL) Scale
The Activities of Daily Living (ADL) scale, developed by American scholars Lawton and Brody in 1969, is a medical assessment tool composed of the Physical Self-Maintenance Scale (PSMS) and the Instrumental Activities of Daily Living (IADL). It is mainly used to evaluate subjects' functional levels in basic living skills such as feeding, dressing and mobility, as well as the ability to use instrumental tools. Constructed from two dimensions including PSMS and IADL, the scale contains a total of 10 assessment items.
Time frame: Baseline. week 12, week 24
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 5 months after the start.
Of 492 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 5 months is below that.
Counting every sponsor, half of 503 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Yueyang Integrated Medicine Hospital